OSE Immuno
OSE Immuno
OSE
EURONEXT
6.45
EUR
-3.30%
About
OSE Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company, engaged in clinical stage biotechnological sector. It develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases.
The Company's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. It provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 156.5K |
| Three Month Average Volume | 3.5M |
| High Low | |
| Fifty-Two Week High | 8.63 EUR |
| Fifty-Two Week Low | 3.025 EUR |
| Fifty-Two Week High Date | 22 May 2024 |
| Fifty-Two Week Low Date | 11 Sep 2023 |
| Price and Volume | |
| Current Price | 8.18 EUR |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 9.41% |
| Thirteen Week Relative Price Change | 7.09% |
| Twenty-Six Week Relative Price Change | 74.42% |
| Fifty-Two Week Relative Price Change | 140.18% |
| Year-to-Date Relative Price Change | 88.54% |
| Price Change | |
| One Day Price Change | 3.02% |
| Thirteen Week Price Change | 2.38% |
| Twenty-Six Week Price Change | 67.62% |
| Five Day Price Change | 13.45% |
| Fifty-Two Week Price Change | 151.69% |
| Year-to-Date Price Change | 91.12% |
| Month-to-Date Price Change | 3.02% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.06432 EUR |
| Book Value Per Share (Most Recent Quarter) | 1.06432 EUR |
| Tangible Book Value Per Share (Last Fiscal Year) | -1.08521 EUR |
| Tangible Book Value Per Share (Most Recent Quarter) | -1.08521 EUR |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.99253 EUR |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.11384 EUR |
| Revenue Per Share (Trailing Twelve Months) | 0.11384 EUR |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 EUR |
| Dividend Per Share (Trailing Twelve Months) | 0 EUR |
| Dividend Per Share (5 Year) | -99999.99 EUR |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.17589 EUR |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.18036 EUR |
| Normalized (Last Fiscal Year) | -1.18609 EUR |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.17589 EUR |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.18036 EUR |
| Including Extraordinary Items (Last Fiscal Year) | -1.17589 EUR |
| Including Extraordinary Items (Trailing Twelve Months) | -1.18036 EUR |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.86498 EUR |
| Cash Per Share (Most Recent Quarter) | 0.86498 EUR |
| Cash Flow Per Share (Last Fiscal Year) | -0.99478 EUR |
| Cash Flow Per Share (Trailing Twelve Months) | -0.97765 EUR |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.01037 EUR |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -72 |
| Cash Flow Revenue (Trailing Twelve Months) | -888 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -1,042.70% |
| Pretax Margin (Last Fiscal Year) | -1,042.70% |
| Pretax Margin (5 Year) | -95.13% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -1,032.15% |
| Operating Margin (Trailing Twelve Months) | -1,032.15% |
| Operating Margin (5 Year) | -94.39% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -1,032.87% |
| Net Profit Margin (Trailing Twelve Months) | -1,032.87% |
| Net Profit Margin (5 Year) | -94.71% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -23.94% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -61.46% |
| Revenue Growth (3 Year) | -38.07% |
| Revenue Change (Trailing Twelve Months) | -87.83% |
| Revenue Per Share Growth | -41.57% |
| Revenue Growth (5 Year) | -40.23% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -17.11% |
| Total Debt (5 Year) | 59.33% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 36.18% |
| EPS Change (Trailing Twelve Months) | -23.14% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 27.1M |
| Net Debt (Last Fiscal Year) | 27.1M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 80 |
| Price to Sales (Trailing Twelve Months) | 80 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 8 |
| Price to Book (Most Recent Quarter) | 8 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 168 |
| Long Term Debt to Equity (Most Recent Quarter) | 168 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -19,997,000 |
| Free Cash Flow (Trailing Twelve Months) | -19,765,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -55 |
| Net Interest Coverage (Trailing Twelve Months) | -56 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 199 |
| Total Debt to Equity (Most Recent Quarter) | 199 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -26.46% |
| Return on Assets (Trailing Twelve Months) | -26.46% |
| Return on Assets (5 Year) | -17.17% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -82.70% |
| Return on Equity (Trailing Twelve Months) | -82.70% |
| Return on Equity (5 Year) | -32.46% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -33.15% |
| Return on Investment (Trailing Twelve Months) | -33.15% |
| Return on Investment (5 Year) | -20.55% |